{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:27:05Z","timestamp":1792794425892,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"DOI":"10.1186\/s13256-024-04773-z","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:01:41Z","timestamp":1727481701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["BRAF mutant PD-L1 positive metastatic musculoskeletal lesions from primary lung adenocarcinoma treated with combination vemurafenib and pembrolizumab: a case report"],"prefix":"10.1186","volume":"18","author":[{"given":"Corazon A.","family":"Ngelangel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florge Francis","family":"Sy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,28]]},"reference":[{"key":"4773_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1634\/theoncologist.2016-0458","volume":"22","author":"C Baik","year":"2017","unstructured":"Baik C, Myall N, Wakelee H. Targeting BRAF-mutant non-small cell lung cancer: from molecular profiling to rationally designed therapy. Oncologist. 2017;22:1\u201311.","journal-title":"Oncologist"},{"key":"4773_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/978-3-319-40389-2_8","volume":"170","author":"T Stinchcombe","year":"2016","unstructured":"Stinchcombe T. Targeted therapies for lung cancer. Lung Cancer, Cancer Treat Res. 2016;170:165\u201382.","journal-title":"Lung Cancer, Cancer Treat Res"},{"issue":"3","key":"4773_CR3","first-page":"244","volume":"2","author":"J Sachez-Torres","year":"2013","unstructured":"Sachez-Torres J, Viteri S, Molina M, Rosell R. BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors. Transl Lung Cancer Res. 2013;2(3):244\u201350.","journal-title":"Transl Lung Cancer Res"},{"issue":"824","key":"4773_CR4","first-page":"1","volume":"20","author":"K Pawelczyk","year":"2019","unstructured":"Pawelczyk K, Piotrowska A, Ciesielska U, Jablonska K, Gletzel-Plucinska N, Crzegrzolka J, Podhorska-Okolow M, Dziegel P, Nowinska K. Role of PD-L1 expression in non-small cell lung cancer and their prognostic significance according to clinicopathological factors and diagnostic markers. Int J Mol Sci. 2019;20(824):1\u201315.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4773_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.31557\/APJCP.2022.23.1.131","volume":"23","author":"R Pandey","year":"2021","unstructured":"Pandey R, Shukla S, Husain N, Islam MH, Hadi R, Tripathi KS, Singhal A. Correlation between programmed death ligand-1 (PD-L1) expression and driver gene mutations in non-small cell lung carcinoma- adenocarcinoma phenotype. Asian Pac J Cancer Prev. 2021;23(1):131\u201342.","journal-title":"Asian Pac J Cancer Prev"},{"key":"4773_CR6","first-page":"1","volume":"12","author":"C Li","year":"2020","unstructured":"Li C, Liu K, Xie Z, Zhu F, Cheng B, Liang H, Li J, Xiong S, Chen Z, Liu Z, Zhao Y, Ou L, Zhong R, Wang W, Huang J, Sun J, Zhang C, Weng L, He J, Liang W, Pan Z. PD-L1 expression with respect to driver mutations in non-small cell lung cancer in an Asian population: a large study of 1370 cases in China. Therapeut Adv Med Oncol. 2020;12:1\u201310.","journal-title":"Therapeut Adv Med Oncol"},{"key":"4773_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.lungcan.2018.07.044","volume":"124","author":"E Dudnik","year":"2018","unstructured":"Dudnik E, Bshara E, Grubstein A, Fridel L, Shocat T, Roisman LC, Ilouze M, Rozenblum AB, Geva S, Zer A, Rotem O, Allen AM, Peled N. Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): outcomes with immune check-point inhibitors (ICPi). Lung Cancer. 2018;124:117\u201324.","journal-title":"Lung Cancer"},{"issue":"8","key":"4773_CR8","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.jtho.2018.04.024","volume":"13","author":"E Dudnik","year":"2018","unstructured":"Dudnik E, Peled N, Nechushtan H, Wollner M, Onn A, Agbarya A, Moskovitz M, Keren S, Popovits-Hadari N, Urban D, Mishaeli M, Zer A, Allen AM, Rabinovich NM, Rotem O, Kuznetsov T, Shochat T, Toisman LC, Bar J. BRAF mutant lung cancer: PD-L1 expression, tumor mutational burden, microsatellite instability status and response to immune check-point inhibitors. J Thoracic Oncol. 2018;13(8):1128\u201337.","journal-title":"J Thoracic Oncol"},{"key":"4773_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz167","author":"J Mazieres","year":"2019","unstructured":"Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van den Heuvel M, Neal J, Peled N, Fruh M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild DI, Bironzao P, Martinez-Marti A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, Camidge DR, Zalcman G, Novello S, Ou SI, Milia J, Gaurschi O. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019. https:\/\/doi.org\/10.1093\/annonc\/mdz167.","journal-title":"Ann Oncol"},{"key":"4773_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.04.006","author":"A Leonetti","year":"2018","unstructured":"Leonetti A, Facchinetti F, Rossi G, Minari R, Conti A, Friboulet L, Tiseo M, Planchard D. BRAF in non-small cell lung cancer (NSCLC): pickaxing another brick in the wall. Cancer Treat Rev Cancer Treat Rev. 2018. https:\/\/doi.org\/10.1016\/j.ctrv.2018.04.006.","journal-title":"Cancer Treat Rev Cancer Treat Rev"},{"issue":"6","key":"4773_CR11","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.21037\/tlcr.2019.10.22","volume":"8","author":"C O\u2019Leary","year":"2019","unstructured":"O\u2019Leary C, Andelkovic V, Ladwa R, Pavlakis N, Zhou C, Hirsch F, Richard D, O\u2019Byrne K. Targeting BRAF mutations in non-small cell lung cancer. Transl Lung Cancer Res. 2019;8(6):1119\u201324.","journal-title":"Transl Lung Cancer Res"},{"key":"4773_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006552","volume":"96","author":"G Cui","year":"2017","unstructured":"Cui G, Liu D, Li W, Fu X, Liang Y, Li Y, Shi W, Chen X, Zhao S. A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer. Medicine. 2017;96: e6552.","journal-title":"Medicine"},{"key":"4773_CR13","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1200\/JCO.2011.35.9638","volume":"29","author":"A Marchetti","year":"2011","unstructured":"Marchetti A, Felicioni L, Malatesta S, Sciarrotta MG, Guetti L, Chella A, Viola P, Pullara C, Mucilli F, Buttitta F. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29:3574\u20139.","journal-title":"J Clin Oncol"},{"key":"4773_CR14","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1158\/1078-0432.CCR-13-0657","volume":"19","author":"S Cardarella","year":"2013","unstructured":"Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C, Yeap BY, Sholl LM, Johnson BE, Janne PA. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res. 2013;19:4532\u201340.","journal-title":"Clin Cancer Res"},{"key":"4773_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad7118","author":"W Zou","year":"2016","unstructured":"Zou W, Wolchok JD, Chen L. PD-L1 (B7\u2013H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016. https:\/\/doi.org\/10.1126\/scitranslmed.aad7118.","journal-title":"Sci Transl Med"},{"key":"4773_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153954","volume":"11","author":"M Ameratunga","year":"2016","unstructured":"Ameratunga M, Asadi K, Lin X, Walkiewicz M, Murone C, Knight S, Mitchell P, Boutros P, John T. PD-L1 and tumor infiltrating lymphocytes as prognostic markers in resected NSCLC. PLoS ONE. 2016;11: e0153954.","journal-title":"PLoS ONE"},{"issue":"6288","key":"4773_CR17","first-page":"1","volume":"22","author":"E Dantoing","year":"2021","unstructured":"Dantoing E, Piton N, Salaun M, et al. Anti-PD1\/PD-L1 immunotherapy for non-small cell lung cancer with actionable oncogenic driver mutations. Int J Mol Sci. 2021;22(6288):1\u201313.","journal-title":"Int J Mol Sci"},{"key":"4773_CR18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s11523-017-0510-9","volume":"12","author":"O Bylicki","year":"2017","unstructured":"Bylicki O, Paleiron N, Margery J, Guisier F, Vergnenergre A, Robinet G, Auliac JB, Gervais R, Chouaid C. Targeting the PD-1\/PD-L1 immune checkpoint in EGFR-mutated or ALK-translocated non-small-cell lung cancer. Target Oncol. 2017;12:563\u20139.","journal-title":"Target Oncol"},{"key":"4773_CR19","first-page":"1","volume":"11","author":"M Pelster","year":"2019","unstructured":"Pelster M, Amaria R. Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials. Therapeut Adv Med Oncol. 2019;11:1\u201311.","journal-title":"Therapeut Adv Med Oncol"},{"issue":"2","key":"4773_CR20","first-page":"232","volume":"4","author":"A Lopez-Gonzalez","year":"2012","unstructured":"Lopez-Gonzalez A, Huelves M, Garcia AL, Provencio M. Skeletal muscle metastasis from NSCL. J Thorac Dis. 2012;4(2):232\u20134.","journal-title":"J Thorac Dis"},{"key":"4773_CR21","first-page":"609","volume":"34","author":"AA Lozi","year":"2010","unstructured":"Lozi AA, Silconi ZB, Misljenovi N. Metastases to rare locations as the initial manifestation of non-small cell lung cancer: two case reports. Coll Antropol. 2010;34:609\u201312.","journal-title":"Coll Antropol"},{"key":"4773_CR22","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1097\/JTO.0b013e3181b24509","volume":"4","author":"D Pop","year":"2009","unstructured":"Pop D, Nadeemy AS, Venissac N, Guiraudet P, Otto J, Poudenx M, Mouroux J. Skeletal muscle metastasis from non-small cell lung cancer. J Thorac Oncol. 2009;4:1236\u201341.","journal-title":"J Thorac Oncol"},{"key":"4773_CR23","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1002\/1097-0142(19870415)59:8<1530::AID-CNCR2820590824>3.0.CO;2-H","volume":"59","author":"KS Sridhar","year":"1987","unstructured":"Sridhar KS, Rao RK, Kunhardt B. Skeletal muscle metastases from lung cancer. Cancer. 1987;59:1530\u20134.","journal-title":"Cancer"},{"key":"4773_CR24","first-page":"20","volume":"9","author":"A Ryan","year":"2007","unstructured":"Ryan A, Chlabra R, Hughes A. Muscular metastasis, a rare presentation of non-small-cell lung cancer. MedGenMed. 2007;9:20.","journal-title":"MedGenMed"},{"key":"4773_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/BF01753809","volume":"7","author":"L Weiss","year":"1989","unstructured":"Weiss L. Biomechanical destruction of cancer cells in skeletal muscle: a rat-regulator for hematogenous metastasis. Clin Exp Metastasis. 1989;7:483\u201391.","journal-title":"Clin Exp Metastasis"},{"key":"4773_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/0306-9877(80)90079-1","volume":"6","author":"S Seely","year":"1980","unstructured":"Seely S. Possible reasons for the high resistance of muscle to cancer. Med Hypotheses. 1980;6:133\u20137.","journal-title":"Med Hypotheses"},{"key":"4773_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131403","volume":"10","author":"P Wu","year":"2015","unstructured":"Wu P, Wu D, Li L, Chai Y, Huang J. PD-L1 and survival in solid tumors: a meta-analysis. PLoS ONE. 2015;10: e0131403.","journal-title":"PLoS ONE"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04773-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-024-04773-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04773-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:02:00Z","timestamp":1727481720000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-024-04773-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,28]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4773"],"URL":"https:\/\/doi.org\/10.1186\/s13256-024-04773-z","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,28]]},"assertion":[{"value":"7 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A copy of the written consent is available for review by the Editor-in-Chief of this journal. With the patient\u2019s consent, ethical approval was given.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There is no competing interest on behalf of the authors in reporting this case.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"450"}}